Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer research: Viennese start-up breaks new ground in drug discovery

21.07.2020

The new start-up QUANTRO Therapeutics at the Vienna BioCenter uses innovative transcriptome profiling technologies in a novel drug discovery pipeline to identify and develop effective anti-tumor therapeutics. The company is a spin-off resulting from the long-standing research cooperation between the institutes IMP and IMBA as well as the pharmaceutical company Boehringer Ingelheim and the Austrian Academy of Sciences. QUANTRO received seed-investment by Boehringer Ingelheim Venture Fund and Evotec and will soon expand its research team.

Cancer is a leading cause of death and one of the most complex challenges to modern medicine. By employing cutting-edge technologies that precisely measure the effects of candidate targets and drugs on the fundamental process of transcription, the new start-up company QUANTRO Therapeutics strives to radically change the precision and scope of cell-based drug screening.


Stefan Ameres and Johannes Zuber

(c) Quantro/Schedl

QUANTRO's primary focus will be on the identification and development of novel chemistry that interferes with cancer-associated transcription factors, a class of particularly promising targets that have so far remained largely inaccessible for drug therapy.

The masterminds behind QUANTRO are the scientists Stefan Ameres from the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), and Johannes Zuber from the Research Institute of Molecular Pathology (IMP), which is sponsored mainly by the pharmaceutical company Boehringer Ingelheim.

Stefan Ameres is the developer of SLAMseq, a time-resolved transcriptomics technology that QUANTRO will use in its operation: "SLAMseq opens up new experimental avenues to systematically quantifying transcriptional activities in living cells. Our ability to resolve the fingerprints of disease-causing transcriptional programs will enable us to break new ground in pharmaceutical research for the development of unprecedented therapeutic interventions.”

Johannes Zuber is a physician and a recognized expert in functional cancer genetics. "Transcription factors govern the identity of tumor cells and have long been considered promising therapeutic targets. At QUANTRO we are combining several cutting-edge technologies in an unprecedented drug discovery pipeline to finally exploit transcription factors for cancer therapy" says Zuber.

The founding of QUANTRO as a spin-off company based on technologies from the partnership between the research institutes IMP and IMBA showcases that research cooperation not only produces excellent scientific results, but also makes a valuable contribution to the economic development of biotechnology in Vienna, according to Michael Krebs* and Harald Isemann, who supported the spin-off as managing directors of IMBA and IMP. Both institutes are part of the Vienna BioCenter, the largest life science cluster in Austria with more than 1800 employees.

QUANTRO was able to win two renowned investors in its seed financing round: The Boehringer Ingelheim Venture Fund and the drug-discovery and development company Evotec.

Dieter Nachtigall, a chemist with more than 20 years of experience in pharmaceutical research and development and with more than 10 years of responsibility in senior executive management positions at Boehringer Ingelheim, was appointed CEO of QUANTRO Therapeutics GmbH.

QUANTRO has moved into state-of-the-art laboratories in the new start-up labs of the Vienna Business Agency in the recently completely renovated building VBC6 and will soon bring more employees on board.

*Michael Krebs was the Managing Director of IMBA until 30.06.2020.

About IMP, IMBA and the Vienna BioCenter

The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by Boehringer Ingelheim. With over 200 scientists from 40 countries, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. www.imp.ac.at

IMBA - Institute of Molecular Biotechnology - is one of the leading biomedical research institutes in Europe focusing on cutting-edge stem cell technologies, functional genomics, and RNA biology. IMBA is a subsidiary of the Austrian Academy of Sciences, the leading national sponsor of non-university academic research. www.imba.oeaw.ac.at

Both IMP and IMBA are part of the Vienna BioCenter, one of Europe’s most dynamic life science hubs with 1,800 employees from 70 countries in four research institutes, three universities and around 30 biotech companies. www.viennabiocenter.org  

About QUANTRO Therapeutics GmbH
QUANTRO Therapeutics (“QUANTRO”) is a research-based entity that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programs in cancer and other diseases. QUANTRO will assemble a highly innovative drug-discovery pipeline that employs time-resolved RNA sequencing and comparative transcriptomics to identify and develop drug candidates interfering with transcriptional regulators. The first focus will be on cancer-associated transcription factors, which so far have been unamenable to pharmacologic intervention. QUANTRO was founded as a spin-off of the Institute of Molecular Biotechnology (“IMBA”) and the Research Institute of Molecular Pathology (“IMP”), both located in Vienna, Austria. Seed investors are Boehringer Ingelheim Venture Fund and Evotec. For more information: www.quantro-tx.com

Weitere Informationen:

https://www.imba.oeaw.ac.at/about-imba/general-news-press/new-startup-quantrothe...

Mag. Evelyn Devuyst IMBA Communications | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht Turning carbon dioxide into liquid fuel
06.08.2020 | DOE/Argonne National Laboratory

nachricht Tellurium makes the difference
06.08.2020 | Friedrich-Schiller-Universität Jena

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: ScanCut project completed: laser cutting enables more intricate plug connector designs

Scientists at the Fraunhofer Institute for Laser Technology ILT have come up with a striking new addition to contact stamping technologies in the ERDF research project ScanCut. In collaboration with industry partners from North Rhine-Westphalia, the Aachen-based team of researchers developed a hybrid manufacturing process for the laser cutting of thin-walled metal strips. This new process makes it possible to fabricate even the tiniest details of contact parts in an eco-friendly, high-precision and efficient manner.

Plug connectors are tiny and, at first glance, unremarkable – yet modern vehicles would be unable to function without them. Several thousand plug connectors...

Im Focus: New Strategy Against Osteoporosis

An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

Osteoporosis is the most common age-related bone disease which affects hundreds of millions of individuals worldwide. It is estimated that one in three women...

Im Focus: AI & single-cell genomics

New software predicts cell fate

Traditional single-cell sequencing methods help to reveal insights about cellular differences and functions - but they do this with static snapshots only...

Im Focus: TU Graz Researchers synthesize nanoparticles tailored for special applications

“Core-shell” clusters pave the way for new efficient nanomaterials that make catalysts, magnetic and laser sensors or measuring devices for detecting electromagnetic radiation more efficient.

Whether in innovative high-tech materials, more powerful computer chips, pharmaceuticals or in the field of renewable energies, nanoparticles – smallest...

Im Focus: Tailored light inspired by nature

An international research team with Prof. Cornelia Denz from the Institute of Applied Physics at the University of Münster develop for the first time light fields using caustics that do not change during propagation. With the new method, the physicists cleverly exploit light structures that can be seen in rainbows or when light is transmitted through drinking glasses.

Modern applications as high resolution microsopy or micro- or nanoscale material processing require customized laser beams that do not change during...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“Conference on Laser Polishing – LaP 2020”: The final touches for surfaces

23.07.2020 | Event News

Conference radar for cybersecurity

21.07.2020 | Event News

Contact Tracing Apps against COVID-19: German National Academy Leopoldina hosts international virtual panel discussion

07.07.2020 | Event News

 
Latest News

Rare Earth Elements in Norwegian Fjords?

06.08.2020 | Earth Sciences

Anode material for safe batteries with a long cycle life

06.08.2020 | Power and Electrical Engineering

Turning carbon dioxide into liquid fuel

06.08.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>